Update on aspirin in the treatment and prevention of cardiovascular disease.

Update on aspirin in the treatment and prevention of cardiovascular disease.
复制标题

阿司匹林治疗和预防心血管疾病的最新进展。

DOI:
10.1016/s0002-8703(99)70391-1
复制
发表时间:
1999
影响因子:
4.8
通讯作者:
C. Hennekens
C. Hennekens
中科院分区:
医学2区
文献类型:
--
作者:
C. Hennekens

文献摘要

参考文献

被引文献

相似文献

低剂量阿司匹林对心血管疾病的影响已在3类人群的随机试验中进行了测试:(1)有心血管疾病史的患者;(2)进展性急性心肌梗死(MI)患者;(3)明显健康的受试者。在许多有闭塞性心血管疾病的患者中,阿司匹林可降低非致死性心肌梗死、非致死性卒中和血管性死亡的风险。在急性心肌梗死症状发作后24小时内开始阿司匹林治疗,也可降低非致死性再梗死、非致死性卒中和总心血管死亡的风险。在一级预防试验中,阿司匹林已被证明可以降低男性首次MI的风险,但中风和总心血管死亡的数据不足以得出明确的结论;女性研究的随机数据尚未获得。女性健康研究是一项正在女性卫生保健专业人员中进行的大规模试验,将提供必要的数据来评估阿司匹林在一级预防中的益处和风险的平衡。在此之前,在一级预防中使用阿司匹林的决定应基于医生的临床判断,并考虑作为其他心血管疾病风险因素管理的辅助手段。(Am Heart J 1999;137:S9-S13.)
The effects of low-dose aspirin on cardiovascular disease have been tested in randomized trials in 3 types of populations: (1) patients with a history of cardiovascular disease; (2) patients with evolving acute myocardial infarction (MI), and (3) apparently healthy subjects. In a very wide range of patients with prior occlusive cardiovascular disease, aspirin reduces the risks of nonfatal MI, nonfatal stroke, and vascular death. Initiating aspirin therapy within 24 hours after the onset of symptoms of an acute MI also confers conclusive reductions in the risk of nonfatal reinfarction, nonfatal stroke, and total cardiovascular death. In primary prevention trials, aspirin has been shown to reduce the risk of a first MI in men, but the data on stroke and total cardiovascular death are not sufficient to allow firm conclusions to be drawn; randomized data from studies in women are not yet available. The Women’s Health Study, an ongoing large-scale trial in female health care professionals, will provide the data necessary to assess the balance of benefits and risks of aspirin in primary prevention. Until then, the decision to use aspirin in primary prevention should be based on the clinical judgment of the physician and considered as an adjunct in the management of other cardiovascular disease risk factors. (Am Heart J 1999;137:S9-S13.)
DOI: 10.1136/bmj.299.6710.1247
发表时间: 1989-11-18
影响因子: 105.7
作者:
PAGANINIHILL, A;CHAO, A;HENDERSON, BE
通讯作者: HENDERSON, BE